Crypto Breaking News

US retail diesel prices topped $6.50 a gallon for the first time, extending a war-driven rally that's rippling through the largest economy. Most US drivers don't pump diesel into their cars. But the fuel which goes into trucks, agricultural equipment, power generators, boats, trains, and home-heating systems touches nearly every part of the economy. James Egelhof, Chief US Economist at BNP Paribas, discusses US economic outlook and how fuel prices are impacting the economy.

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Anthropic PBC is partnering with Accenture Plc to test the safety of its advanced artificial intelligence models. Evaluators from Accenture will be embedded and tasked with trying to "break" these models before they're deployed. Bloomberg's Ed Ludlow reports.

Trade Representative Jamieson Greer indicated China and the US remain divided on the terms of a trade truce extension. Asked if a three-to six-month extension was under discussion, Greer said "that's probably the right kind of range" though it's unlikely to be announced this week. He spoke on "Bloomberg Surveillance."

US Trade Representative Jamieson Greer discusses trade talks with China, the possibility of a diesel export ban, and the state of relations with Canada and the renegotiation of the USMCA.

Bob McNally, founder and president at Rapidan Energy Group, explains the potential global market impact if the United States was to ban the export of diesel. McNally says the move by the US "would shatter its reputation as a safe place to invest for a generation." He speaks on "Bloomberg Surveillance."

Federal Reserve Bank of Chicago President Austan Goolsbee warns that the central bank cannot ignore repeated and persistent supply shocks and must respond in a way that may cause economic hardship. Goolsbee calls it "exactly the kind of painful trade-off between employment and inflation that stagflationary shocks always impose on the central bank." He spoke Monday in London.

Beata Manthey, head of European equity strategy at Citi, examines the impact of rising energy prices on bonds and equities. She calls geopolitics "the biggest risk out there" but sees "quite an optimistic pass through" once that is resolved. She speaks on "Bloomberg Surveillance."

Mark McCormick, BMO Capital Markets Chief FX Strategist, joins Bloomberg's Vonnie Quinn on "Bloomberg Brief" to discuss the risks around the wealth effect being a primary driver of consumption in the US.

SoftBank is looking to issue the equivalent of more than $11 billion in what would be one of the biggest junk bond deals ever, according to people familiar with the matter. This comes as the company ramps up its investments in ChatGPT creator OpenAI. Neil Campling reports on Bloomberg Television.

Germany's regional economies will continue to weaken as the far-right Alternative for Germany (AfD) gets stronger, says Marcel Fratzscher, president of DIW Berlin. "People are leaving," Fratzscher tells Bloomberg Television. "And not just people with a migrant background, but Germans and German companies."

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.